Our latest news
Sciety and Sciety Venture Partners invest EUR 5.3 million in Capitainer
Sciety and Sciety Venture Partners recently completed an investment of EUR 5.3 million in Capitainer, a Swedish medtech company that has developed a unique platform for self-sampling of blood, facilitating remote healthcare solutions and personalized medicine. The capital will be…Read more
Sciety invests in a company developing targeted radioimmunotherapy for incurable cancer
Sciety and the network Sciety Venture Partners have invested SEK 68 million in the Swedish radioimmunotherapy company Akiram Therapeutics. The investment company Linc AB participated in the share issue with SEK 20 million. Akiram is developing a new type of…Read more
Are you searching for the next big thing in life science and health tech?
Your search ends here. By joining Sciety Venture Partners, you have the opportunity to invest alongside Sciety in the most promising life science companies. Not only do you benefit from our extensive research and expertise, but you also become part of a network of like-minded investors.
Let us make health and life science innovations reach their full potential. Sign up to join Sciety Venture Partners and start receiving invitations to investor events, investment opportunities and news.
Lots of opportunities, lots to be done
Sweden takes the lead
Sweden is Northern Europe's most dynamic market for life sciences, with a strong focus on innovation and collaboration. It is in the top five among the world's countries in terms of investment in research and development.
An aging population, increasing incidence of lifestyle diseases, and more demanding health care consumers are increasing demand for drugs, innovative medical technology, and digital solutions.
Precision medicine and genomics
The biotechnological revolution creates new opportunities to develop customized treatments for each individual disease case. This in turn leads to increased demand for precision diagnostics and technology solutions in areas such as genomics.
Growth companies on top
Growth companies in the biopharma sector are behind the majority of all new drugs approved by the FDA. Increasing numbers of partnership agreements are also being signed between Big Pharma and smaller companies.
More tech in healthcare
Digital solutions are being implemented at a fast pace. Efforts to streamline healthcare processes, cost savings, and improved health care quality as well as increased demand for on-demand care are drivers behind this trend.
Life saving advancements
Over the past 100 years, the global average life expectancy has more than doubled and is now 73 years. The child mortality rate in the world has declined by nearly 75% since 1950. Significant medical advances are one of the causes behind this positive development.
Are you looking for an investor that will support you in turning your life science or health tech innovation into a thriving business?
We got you covered.
At Sciety, we understand that securing an investment is just the first step in building a successful company. That is why our investment is more than just financial capital – it is a long-term partnership.
Our team of experts, including researchers, clinicians, entrepreneurs, and business professionals, brings a unique combination of skills to the table. We are dedicated to helping you reach your full potential and will be by your side every step of the way. Want to learn more?
Companies we are investing in right now
We are currently investing in one or more companies that passed our rigorous selection process. Please login or create an account to learn more and co-invest with us.
Some of our portfolio companies
Encare not only contributes to more cost-effective surgery but also reduces complications and saves lives through their proprietary software solution that helps hospitals implement best practice throughout the entire care chain – from diagnosis and preparation to surgery and rehabilitation.
Capitainer offers a unique platform for the self-sampling of fingertip blood and plasma based on a patented microfluidic technology. The products enable easy home sampling with high precision, delivering value across the entire care chain.
Akiram has developed a new type of targeted radioimmunotherapy with the potential to become first-in-class. In animal studies, the survival rate has been 100%, and the tumours have been eradicated with just one treatment.
PharmNovo develops a novel drug for nerve pain, where there is a high, unmet need for effective and safe treatments. The candidate PN6047 shows effective pain relief in animal models, without the negative side effects associated with existing drugs.